Evidence map›Paper›PMID 24318514›Full record

ArticleHuman cell2014

Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility.

Masayuki Sakiyama, Hirotaka Matsuo, Seiko Shimizu, Toshinori Chiba, Akiyoshi Nakayama, Yuzo Takada, Takahiro Nakamura, Tappei Takada, Emi Morita, Mariko Naito and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 1 country.

Masayuki SakiyamaDepartment of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Hirotaka Matsuo
Seiko Shimizu
Toshinori Chiba
Akiyoshi Nakayama
Yuzo Takada
Takahiro Nakamura
Tappei Takada
Emi Morita
Mariko Naito
Kenji Wakai
Hiroki Inoue
Seishiro Tatsukawa
Junki Sato
Kazumi Shimono
Toshiaki Makino
Takahiro Satoh
Hiroshi Suzuki
Yoshikatsu Kanai
Nobuyuki Hamajima
Yutaka Sakurai
Kimiyoshi Ichida
Toru Shimizu
Nariyoshi Shinomiya
National Defense Medical College · JPNagoya University · JPUniversity of Tokyo Hospital · JPMidorigaoka Hospital · JPNagoya City University · JPOsaka University · JPToho University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout is a common disease resulting from hyperuricemia which causes acute arthritis. Recently, genome-wide association studies revealed an association between serum uric acid levels and a common variant of leucine-rich repeat-containing 16A (LRRC16A) gene. However, it remains to be clarified whether LRRC16A contributes to the susceptibility to gout. In this study, we investigated the relationship between rs742132 in LRRC16A and gout. A total of 545 Japanese male gout cases and 1,115 male individuals as a control group were genotyped. rs742132 A/A genotype significantly increased the risk of gout, conferring an odds ratio of 1.30 (95 % CI 1.05-1.60; p = 0.015). LRRC16A encodes a protein called capping protein ARP2/3 and myosin-I linker (CARMIL), which serves as an inhibitor of the actin capping protein (CP). CP is an essential element of the actin cytoskeleton, which binds to the barbed end of the actin filament and regulates its polymerization. In the apical membrane of proximal tubular cells in the human kidney, the urate-transporting multimolecular complex (urate transportsome) is proposed to consist of several urate transporters and scaffolding proteins, which interact with the actin cytoskeleton. Thus, if there is a CARMIL dysfunction and regulatory disability in actin polymerization, urate transportsome may be unable to operate appropriately. We have shown for the first time that CARMIL/LRRC16A was associated with gout, which could be due to urate transportsome failure.

Indexed as

Genetic VariationActin CytoskeletonActinsCarrier ProteinsGenetic Predisposition to DiseaseGenotypeGoutHumansMaleMicrofilament ProteinsOrganic Anion TransportersPolymerizationUric AcidActinsCARMIL1 protein, humanCarrier ProteinsMicrofilament ProteinsOrganic Anion Transportersurate transporterUric Acid

Identifiers

PMID24318514
PMCPMC3889988
OpenAlexW2013962760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.